Ikena Oncology Inc reports results for the quarter ended in September 30 - Earnings Summary

ImageneBio

07/11/2024 17:20

* Ikena Oncology Inc  IKNA.OQ  reported a quarterly adjusted
loss
of 21 cents​​ per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -40 cents.  The mean expectation of
three analysts for the quarter was for a loss of 27 cents per
share. Wall Street expected results to range from -33 cents
to -21 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Ikena Oncology Inc's reported EPS for the quarter was a
loss
of 21 cents​.
    * The company reported a quarterly loss of $10.23 million.
    * Ikena Oncology Inc shares had fallen by 0.6% this
quarter and
lost 12.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 2.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Ikena Oncology
Inc is $4.00 
This summary was machine generated from LSEG data November 7 at
05:19 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.27          -0.21          Beat
 Jun. 30 2024      -0.35          -0.28          Beat
 Mar. 31 2024      -0.41          -0.33          Beat
 Dec. 31 2023      -0.43          -0.47          Missed